Treatment of proteinuria with low-molecular-weight heparin after renal transplantation

Transplant International

Volumn 17, Issue 8, 2004, Pages 468-472

  Krzossok, Stefan ^a   Birck, Rainer ^a   Koeppel, Hannes ^a   Schnülle, Peter ^b   Waldherr, Rüdiger ^a   Van Der Woude, Fokko J ^a   Braun, Claude ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Institute for Clinical Pathology   (Germany)

Author keywords

ACE inhibition; Kidney transplantation; Low molecular weight heparin; Proteinuria

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOW MOLECULAR WEIGHT HEPARIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NADROPARIN; PREDNISONE;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CASE REPORT; DIABETIC NEPHROPATHY; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL HEMORRHAGE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOSIS; URINALYSIS;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROTEINURIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 5444270344     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00147-004-0743-2     Document Type: Article

References (23)

1. First MR, Vaidya PN, Maryniak RK, et al. Proteinuria following transplantation. Correlation with histopathology and outcome. Transplantation 1984; 38:607.
2. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103.
3. Kim HC, Park SB, Lee SH, Park KK, Park CH, Cho WH. Proteinuria in renal transplant recipients: incidence, cause, and prognostic importance. Transplant Proc 1994; 26:2134.
4. Ahmad I, Abul-Ezz SR, Walker PD, Bonsib SM, Ketel B, Barri YM. Acute rejection presenting as nephrotic syndrome. Transplantation 2000; 27:2663.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456.
6. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354:359.
7. Oka K, Imai E, Moriyama T, et al. A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor. Nephrol Dial Transplant 2000; 15:689.
8. Jeong HJ, Kim YS, Kwon KW, et al. Segmental glomerulosclerosis in IgA nephropathy after renal transplantation: relationship with proteinuria and therapeutic response to enalapril. Clin Transplant 2003; 17:108.
9. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression: in proteinuric nephropathies, enhanced glomerular protein traffic contributes to interstitial inflammation and renal scarring. Kidney Int 1997; 51:2.
10. Ong AC, Fine LG. Loss of glomerular function and tubulointerstitial fibrosis: Cause or effect? Kidney Int 1994; 45:345.
11. Cheigh JS, Mouradian J, Soliman M, et al. Focal segmental glomerulosclerosis in renal transplants. Am J Kidney Dis 1983; 2:449.
12. Abbott KC, Sawyers ES, Oliver JD 3rd, et al. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 2001; 37:366.
13. Meehan SM, Pascual M, Williams WW, et al. De novo collapsing glomerulosclerosis in renal allografts. Transplantation 1998; 65:1192.
14. Cosio FG, Frankel WL, Pelletier RP, Pesavento TE, Henry ML, Ferguson RM. Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy: implications for graft survival. Am J Kidney 1999; Dis 34:731.
15. Floege J, Eng E, Young BA, Couser WG, Johnson RJ. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangio-proliferative glomerulonephritis. Kidney Int 1993; 43:369.
16. Diamond JR, Karnovsky MJ. Non-anticoagulant protective effect of heparin in chronic aminonucleoside nephrosis. Renal Physiol 1986; 9:366.
17. Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994; 46:797.
18. Myrup B, Hansen PM, Jensen T, et al. Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 1995; 345:421.
19. Tamsma JT, van der Woude FJ, Lemkes HH. Effect of sulfated glycosaminoglycans on albuminuria in patients with overt diabetic (type-I) nephropathy. Nephrol Dial Transplant 1996; 11:182.
20. Solini A, Vergnani L, Ricci F, Crepaldi G. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 1997; 20:813.
21. Castellot JJ Jr, Hoover RL, Harper PA, Karnowsky MJ. Heparin and glomerular epithelial-cell secreted heparin-like species inhibit mesangial cell proliferation. Am J Pathol 1985; 120:427.
22. Gambaro G, van der Woude FJ. Glycosaminoglycans: use in treatment of diabetic nephropathy. J Am Soc Nephrol 2000; 11:359.
23. Braun C, Schultz M, Fang L, et al. Treatment of chronic renal allograft rejection in rats with a low-molecular-weight heparin (reviparin). Transplantation 2001; 72:209.